Cardiac iron load and function in transfused patients treated with deferasirox (the <scp>MILE</scp> study)

Abstract

Once-daily deferasirox over 1 yr significantly increased myocardial T2* and reduced LIC. This confirms that single-agent deferasirox is effective in the management of cardiac iron, especially for patients with myocardial T2* >10 ms (Clinicaltrials.gov identifier: NCT00673608).